Table 1.
Characteristics of patients
| Characteristics | Smoking control | Mild COPD | Moderate COPD | Severe COPD |
|---|---|---|---|---|
| GOLD | - | Stage I | Stage II | Stage III, IV |
| Number of patients | 106 | 69 | 103 | 80 |
| Age (years) | 70.5 ± 9.4 | 72.2 ± 9.3 | 72.5 ± 8.8 | 73.9 ± 8.7 |
| Gender (Male/Female) | (102/4) | (65/4) | (98/5) | (76/4) |
| FVC predict (%) | 97.2 ± 14.2 | 114.1 ± 14.9* | 97.3 ± 16.1 | 75.7 ± 18.1* |
| FEV1/FVC (%) | 77.3 ± 6.1 | 64.5 ± 5.1* | 52.8 ± 9.1* | 39.3 ± 10.4* |
| FEV1% predict | 96.1 ± 13.5 | 96.3 ± 13.3 | 64.5 ± 8.8* | 37.5 ± 8.1* |
| LAA (%) | 5.5 ± 6.1 | 10.7 ± 10.0 | 14.6 ± 10.7* | 22.7 ± 14.6* |
| Smoking (Pack years) | 61.4 ± 38.5 | 58.1 ± 33.7 | 60.5 ± 30.7 | 63.2 ± 29.2 |
| Current smoker (no.) | 31 | 22 | 29 | 19 |
| Medication (no.) | ||||
| LABA | - | 17 | 49 | 50 |
| LAMA | - | 17 | 46 | 55 |
| ICS | - | 11 | 36 | 38 |
| CRP (mg/dl) | 0.24 ± 0.34 | 0.31 ± 0.48 | 0.39 ± 0.77 | 0.46 ± 0.92 |
COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Obstructive Lung Disease, FEV1 % predict Forced Expiratory Volume in 1 s % predicted, LAA Low attenuation area; change in FEV1 as a percent of baseline FEV1, LABA Long acting beta 2 agonist, LAMA Long acting muscarinic antagonist, ICS Inhaled corticosteroid
Values are expressed as means ± SD. * p < 0.05 vs smoking control